Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 6/20 | 0.50 |
| ▸ | SCN8A | Q9UQD0 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8085163 | 0.96 | SCN1A (0.47) | SCN1ASCN8ASMN1; SMN2MCHR1KCNH2 | |
| SCHEMBL4245768 | 0.92 | NPC1 (0.48) | SCN1ASCN8ASMN1; SMN2ROCK1ROCK2 | |
| SCHEMBL4246391 | 0.91 | SCN1A (0.42) | SCN1ASCN8ASMN1; SMN2GAA | |
| SCHEMBL8104062 | 0.90 | ACHE (0.48) | SCN1ASCN8AMCHR1 | |
| SCHEMBL8100160 | 0.90 | HTR1A (0.45) | SCN1ASCN8AROCK1ROCK2 | |
| SCHEMBL8095680 | 0.90 | PDE4B (0.46) | SCN1ASCN8AKCNH2SCN5ASCN9A | |
| SCHEMBL5530200 | 0.89 | SMN1; SMN2 (0.50) | SCN1ASCN8ASMN1; SMN2MCHR1KCNH2 | |
| SCHEMBL8095861 | 0.89 | KCNH2 (0.41) | SCN1ASCN8ASMN1; SMN2KCNH2SCN5A | |
| SCHEMBL13945322 | 0.89 | SCN9A (0.46) | SCN1ASCN8ASCN9AKDM4E | |
| SCHEMBL8102253 | 0.89 | HTR1A (0.47) | SCN1ASCN8AMCHR1MAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | SCN1A 89/4885SCN8A 103/4885SMN1; SMN2 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.